<DOC>
	<DOC>NCT01350102</DOC>
	<brief_summary>The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGelÂ® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with and without vitamin C supplementation, will be done to evaluate impact on time to wound closure.</brief_summary>
	<brief_title>The Relationship of Hemoglobin A1c and Diabetic Wound Healing</brief_title>
	<detailed_description>This is a prospective randomized controlled study evaluating the relationship of hemoglobin A1c in diabetic wound healing. Length of time for wound closure will be compared using four treatment options.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Bacitracin</mesh_term>
	<criteria>&gt;18 years of age Diabetic (Type I and Type II) Ulceration of the foot at least one centimeter in width/length Ulceration at least 0.2 centimeters in depth Ulceration width/length &gt; 7.5 centimeters Wound depth &gt; 1.25 centimeters Purulent, excessive drainage and/or other signs of infection (i.e. erythema, edema, warmth) Inability to provide informed consent Inability to swallow pills (vitamin C supplement) Patients with concurrent renal problems Patients with medication contraindications to Vitamin C and/or topical wound dressings</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Adult</keyword>
</DOC>